These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 2499293)
1. The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience. Brettler DB; Forsberg AD; Levine PH; Aledort LM; Hilgartner MW; Kasper CK; Lusher JM; McMillan C; Roberts H Arch Intern Med; 1989 Jun; 149(6):1381-5. PubMed ID: 2499293 [TBL] [Abstract][Full Text] [Related]
2. Inhibitor antibodies to factor VIII and factor IX: management. Lusher JM Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411 [TBL] [Abstract][Full Text] [Related]
3. [Comparison of anti-human and anti-porcine factor VIII antibody titers in patients with hemophilia]. Windyga J; Rzymkiewicz L; Lopaciuk S Acta Haematol Pol; 1996; 27(1):27-31. PubMed ID: 8629440 [TBL] [Abstract][Full Text] [Related]
4. Use of porcine factor VIII for surgical procedures in hemophilia A patients with inhibitors. Lozier JN; Santagostino E; Kasper CK; Teitel JM; Hay CR Semin Hematol; 1993 Apr; 30(2 Suppl 1):10-21. PubMed ID: 8480192 [TBL] [Abstract][Full Text] [Related]
5. [Outcome of hemorrhage treatment in children with hemophilia A related to factor VIII inhibitor]. Klukowska A; Zieleniewska B Acta Haematol Pol; 1994; 25(4):349-54. PubMed ID: 7847036 [TBL] [Abstract][Full Text] [Related]
6. [Recombinant activated Factor VII (Novoseven Novo Nordisk) for hemostasis in acquired Factor VIII-inhibitor hemophilia]. Meili EO; Dazzi H; von Felten A Schweiz Med Wochenschr; 1995 Mar; 125(9):405-11. PubMed ID: 7892567 [TBL] [Abstract][Full Text] [Related]
7. Hemophilia. Strategies for the treatment of inhibitor patients. Ingerslev J Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863 [TBL] [Abstract][Full Text] [Related]
8. Treatment of anti-factor VIII antibodies. Blatt PM; White GC; McMillan CW; Roberts HR Thromb Haemost; 1977 Aug; 38(2):514-23. PubMed ID: 579493 [TBL] [Abstract][Full Text] [Related]
9. Use of porcine factor VIII in the management of seventeen patients with factor VIII antibodies. Gatti L; Mannucci PM Thromb Haemost; 1984 Jul; 51(3):379-84. PubMed ID: 6437005 [TBL] [Abstract][Full Text] [Related]
10. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352 [TBL] [Abstract][Full Text] [Related]
11. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. Sjamsoedin LJ; Heijnen L; Mauser-Bunschoten EP; van Geijlswijk JL; van Houwelingen H; van Asten P; Sixma JJ N Engl J Med; 1981 Sep; 305(13):717-21. PubMed ID: 6790990 [TBL] [Abstract][Full Text] [Related]
12. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. Lusher JM; Arkin S; Abildgaard CF; Schwartz RS N Engl J Med; 1993 Feb; 328(7):453-9. PubMed ID: 8421474 [TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin SDH in previously treated patients with severe haemophilia A. Wolf DM; Rokicka-Milewska R; Lopaciuk S; Skotnicki AB; Klukowska A; Laguna P; Windyga J; Kotitschke R; Struff WG Haemophilia; 2004 Sep; 10(5):438-48. PubMed ID: 15357768 [TBL] [Abstract][Full Text] [Related]
14. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate. Peerlinck K; Arnout J; Di Giambattista M; Gilles JG; Laub R; Jacquemin M; Saint-Remy JM; Vermylen J Thromb Haemost; 1997 Jan; 77(1):80-6. PubMed ID: 9031454 [TBL] [Abstract][Full Text] [Related]
15. Inhibitors in young boys with haemophilia. Lusher JM Baillieres Best Pract Res Clin Haematol; 2000 Sep; 13(3):457-68. PubMed ID: 11030045 [TBL] [Abstract][Full Text] [Related]
16. Treatment of patients with hemophilia A and inhibitors to factor FVIII with cimetidine. Ambriz Fernandez R; Quintana Gonzalez S; Martinez Murillo C; Dominguez Garcia V; Rodriguez Moyado H; Collazo Jaloma J Arch Med Res; 1996; 27(1):15-8. PubMed ID: 8867361 [TBL] [Abstract][Full Text] [Related]
17. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. Nilsson IM; Berntorp E; Zettervall O N Engl J Med; 1988 Apr; 318(15):947-50. PubMed ID: 3127711 [TBL] [Abstract][Full Text] [Related]
18. Lack of immune response to mouse IgG in hemophilia A patients treated chronically with Monoclate, a monoclonal antibody affinity purified factor VIII preparation. Davis HM; Brown SK; Nash DW; Pennetti AM; Salzman PM; Schreiber AB; Haimovich J Thromb Haemost; 1990 Jun; 63(3):386-91. PubMed ID: 2119524 [TBL] [Abstract][Full Text] [Related]
19. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group. Schwartz RS; Abildgaard CF; Aledort LM; Arkin S; Bloom AL; Brackmann HH; Brettler DB; Fukui H; Hilgartner MW; Inwood MJ N Engl J Med; 1990 Dec; 323(26):1800-5. PubMed ID: 2123300 [TBL] [Abstract][Full Text] [Related]
20. New protocol for immune tolerance induction in acquired hemophilia. Nemes L; Pitlik E Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]